When people of RMR management, who were dealing with SNH for a longtime buy its stock at price around $29#$%$ make sense to buy it now
at around $15.
With new arrangement RMR has a vested interest to see SNH prosper.
I'm not sure RMR pay dividend at regular basis
on 2015/06/05 Dortnoy Adam bought 1,055,250 shares at $19.95 /sh paid a total of $21,052,2002. There are several similar large purchase Why don't you go to insider security site and check it for yourself.
Search 2015 insider trading for SNH
Check the it against list of the RMR board
Most of large buy trade are by the RMR board member.NO selling
Sentiment: Strong Buy
Managements of RMR have recently bought substantial mount of SNH stocks. This a vote of confidence from the people who know the real financial condition on SNH.
Sentiment: Strong Buy
MYL has an estimated eps of $4.30 for this year.
It has an estimated growth of 20.8.
Therefore its share price should be $4.30 x 20.8 = $89.44 conservatively.
Instead of NAGGING we should make it clear to the management:
PLEASE DO NOT ROCK THE BOAT if you do we push you of the board.
MYL has by far better valuation than any competitor . Check it for yourself:
Sales growth- 30% vs 19%
Earning growth 19% vs -90% !!!
PE 10.3 vs 11.3
EPS $1.80 vs 0.26
PEG 0.86 vs 1.9
As you can see in all categories MYL has better valuation. Recent analyst up grade is a plus.
IF THE MANGEMENT DO NOTHING JUST SHUTUP, AND ENJOY THEIR UNDESEVING BENEFITS THIS STOCK WILL BE TRADING IN SEVENTIES SOON.
They released 1Q this evening so long can have a nice sleep tonight with a nice smile on their face. Shorts? they should take as many sleeping pills they can find. 2015 is going to a nice, rewarding and happy year for LONGS
Based on current divy the new valuation is 10.13x1.29/2.90=$ 4.50
There was so much hope and hype about continuing the current payout this early reduction will have a disastrous result on the stock price. Good luck to all.
Sanofi revamps 'underperforming' U.S. sales team under new diabetes chief
Among those changes: Sanofi brought in Andrew Purcell to head up its U.S. diabetes business; he joined the company a few months ago, spokeswoman Susan Brooks told FiercePharmaMarketing.
And then there's the change at the top of North America Pharmaceuticals. This summer, U.S. chief Anne Whitaker left Sanofi for a CEO post at Synta. Obviously, she was deeply involved in the diabetes business, because it's among Sanofi's biggest. There's been no suggestion that she was forced out; obviously, she had a job waiting for her. So, her departure may simply illustrate the problems in the company's U.S. operations. But Weinberg did mention execution issues among local management. After Whitaker left, Sanofi quickly brought in Jez Moulding, who previously headed up its operations in Japan, to replace her.
"Under their leadership, we are assessing and evolving our commercial approach to continue to offer our existing treatments to help people living with diabetes," Brooks said in an emailed statement. "We are also preparing for the upcoming launch of Afrezza in Q1 2015 and the potential launch of Toujeo in 2015."
The lawyers do as the lawyers do,but in this case they will not go anywhere. There was no intention to defraud the stock holder. The management was BUYING the stock. They lost as anybody else. When they discovered the error they took the necessary action. It takes time for stock to recover but it will.THERE WAS NO INTENTION MISSLEAD.
You can not expect that a veterinarian know much about afrezza.
TheStreet Ratings team rates PROSPECT CAPITAL CORP as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate PROSPECT CAPITAL CORP (PSEC) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income, expanding profit margins, impressive record of earnings per share growth and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow."